Monthly Archives: November 2018
Meharry-Vanderbilt Alliance holds first meeting for All of Us participant partners
The All of Us Research Project held the first in-person retreat for newly selected participant partners to discuss important issues facing precision medicine. The Meharry-Vanderbilt Alliance has directed the Engagement Core since April 2018. Continue reading
Vanderbilt Public Safety seeks community feedback
Children’s Hospital patient Caroline Lantz has a special night with Maddie and Tae at the CMAs
Caroline Lantz, 5, a patient at Monroe Carell Jr. Children’s Hospital at Vanderbilt, was surprised with tickets to the 52nd annual Country Music Association (CMA) Awards at Nashville’s Bridgestone Arena, along with glamour treatment and a red carpet ap… Continue reading
eStar update: Happy Together feature now available in Care Everywhere
VUMC mourns loss of longtime supporter Ann Robinson
Ann Allen Robinson, 86, died at her home on Friday, Nov. 23 after a lengthy illness. A native of Enid, Oklahoma, she was married to Roscoe R. “Ike” Robinson, MD, who served as Vanderbilt University Medical Center’s Vice Chancellor for Health Affairs fr… Continue reading
Modeling Human Digestive Diseases with CRISPR-Cas9-modified Organoids
Insights into the stem cell niche have allowed researchers to cultivate adult tissue stem cells as organoids that display structural and phenotypic features of healthy and diseased epithelial tissues. Organoids derived from patients’ tissues are used… Continue reading
Correction
Coleman OI, Lobner EM, Bierwirth S, et al. Activated ATF6 induces intestinal dysbiosis and innate immune response to promote colorectal tumorigenesis. Gastroenterology 2018;155:1539–1552. Continue reading
Correction
Zhang S, Nguyen LH, Zhou K, et al. Knockdown of anillin actin binding protein blocks cytokinesis in hepatocytes and reduces liver tumor development in mice without affecting regeneration. Gastroenterology 2018;154:1421–1434. Continue reading
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate to Severe Ulcerative Colitis
α4β7 integrin is a validated target in inflammatory bowel disease. This randomized, phase 2b, placebo-controlled, double-blind study evaluated the efficacy and safety of the anti-α4β7 antibody abrilumab in patients with moderate-to-severe ulcerativ… Continue reading
Histone Demethylase JMJD2D Interacts with Beta-catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice
Wnt signaling contributes to development of colorectal cancer (CRC). We studied interactions between lysine demethylase 4D (KDM4D or JMJD2D) and beta-catenin, a mediator of Wnt signaling, in CRC cell lines and the effects on tumor formation in mice. Continue reading